Literature DB >> 2021426

Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity.

C R Alving1, G M Swartz.   

Abstract

Polyclonal and monoclonal antibodies to cholesterol are readily induced by injecting cholesterol-loaded liposomes containing lipid A as an adjuvant. Analysis of the literature reveals that conjugates of cholesterol, and conjugates of analogues of cholesterol, with heterologous proteins or lipids have been used as antigens in various studies since 1925, and this has led to successful development of immunoassays for steroid hormones. It is concluded that cholesterol is a highly immunogenic molecule. The ability of monoclonal antibodies to cholesterol to react with liposomes containing cholesterol to cause complement-dependent immune damage to the liposomes is strongly influenced by the lipid composition of the liposomes, the amount of cholesterol in the liposomes, and the reaction temperature. The antibodies also react with crystalline cholesterol in a solid-phase ELISA and, depending on the particular monoclonal antibody, immune reactivity may or may not be observed with cholesterol esters, cholesterol analogues, or steroid hormones. Analysis by ELISA has revealed that virtually all normal human sera contain varying levels of naturally occurring IgG and IgM autoantibodies to cholesterol. Naturally occurring autoantibodies to cholesterol are also observed in pigs, but not in guinea pigs. Possible implications of these investigations for theories of immune mechanisms that may have beneficial or detrimental roles in processes of aging, atherosclerosis, and vascular diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021426

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  7 in total

Review 1.  Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups.

Authors:  S M Moghimi; A C Hunter
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

Review 2.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

3.  Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Authors:  Gary R Matyas; Alexander V Mayorov; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Malliga R Iyer; Fuying Li; Zoltan Beck; Kim D Janda; Carl R Alving
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

4.  Plasma factor triggering alternative complement pathway activation by liposomes.

Authors:  K Funato; C Yamashita; J Kamada; S Tominaga; H Kiwada
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

5.  Cholesterol domains enhance transfection.

Authors:  Jamie L Betker; Max Kullberg; Joe Gomez; Thomas J Anchordoquy
Journal:  Ther Deliv       Date:  2013-04

Review 6.  Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.

Authors:  Ninh M La-Beck; Md Rakibul Islam; Maciej M Markiewski
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

7.  Anti-cholesterol antibody levels in hereditary angioedema.

Authors:  Lilian Varga; Adrienn Bíró; Gábor Széplaki; Luca Tóth; Anna Horváth; George Füst; Henriette Farkas
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.